219 results
Page 2 of 11
6-K
EX-4.1
kf3l0qsn4k
19 Oct 23
Report of Foreign Private Issuer
10:36am
424B5
na8majjrz9w1z2npnhys
19 Oct 23
Prospectus supplement for primary offering
10:27am
6-K
EX-99.1
qgop hlna45rwi
17 Oct 23
Purple Biotech Announces $5 Million Registered Direct Offering
8:02am
6-K
EX-99.1
6fvb 85591
13 Oct 23
Report of Foreign Private Issuer
7:09am
6-K
EX-99.1
33ronigtep
6 Oct 23
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
8:01am
6-K
EX-99.1
5jsdd
3 Oct 23
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
8:00am
6-K
EX-99.1
e7m04h5gaxq5sxwmr2
21 Sep 23
Report of Foreign Private Issuer
8:04am
6-K
EX-99.1
2gd3b0hrexg6
13 Sep 23
Report of Foreign Private Issuer
8:39am
6-K
EX-99.1
9vqbcy
22 Aug 23
Purple Biotech Reports Second Quarter 2023 Financial Results
8:22am
6-K
EX-99.1
6elos3ae
11 Jul 23
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
8:20am
6-K
bl1lcii t6bm952s2h
22 May 23
Report of Foreign Private Issuer
5:01pm
F-3/A
imjv n3gfjcm73kvr8
17 May 23
Shelf registration (foreign) (amended)
5:20pm
6-K
EX-99.1
h7nvwdl6to3hyv
16 May 23
Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update
4:01pm
6-K
EX-99.1
ydunw7cbt8d
25 Apr 23
Report of Foreign Private Issuer
8:07am
6-K
EX-99.1
3yw zm3wt
19 Apr 23
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
8:17am
F-3
sokfh uw3
7 Dec 22
Shelf registration (foreign)
9:17pm
6-K
EX-99.1
sv09nwnep fivd0r
15 Nov 22
Report of Foreign Private Issuer
7:03am
6-K
EX-99.1
9wo6xa
9 Nov 22
Report of Foreign Private Issuer
4:11pm
6-K
EX-99.1
wrs6u
8 Nov 22
Purple Biotech Reports Third Quarter 2022 Financial Results
7:56am
6-K
EX-99.1
2o1x0s504z0v2akf1
2 Nov 22
Purple Biotech Appoints Lior Fhima as Chief Financial Officer
7:39am